ESR1 and breast carcinoma: In the phase 3 CheckMate 7FL study, a similar improvement in pCR outcomes was reported among patients with high-risk, early-stage, grade 2/grade 3 ER+/HER2− breast cancer who received nivolumab plus neoadjuvant chemotherapy compared to those who received placebo plus neoadjuvant chemotherapy (24.5% versus 13.8%; odds ratio = 2.05 (95% CI, 1.29‒3.27); P = 0.0021)16.